Overview

Phase 1 Study of PBTZ169

Status:
Completed

Trial end date:
2016-11-01

Target enrollment:

Participant gender:

Summary

Open-label prospective non-comparative safety, tolerability and pharmacokinetics ascending dose randomized cohort study of PBTZ169 (capsules 40 mg) in fasted healthy volunteers after single and multiple oral administration

Phase:

Phase 1

Details

Lead Sponsor:

Nearmedic Plus LLC

Collaborator:

OCT LLC

Treatments:

Macozinone